Eli Lilly and Company is a Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology.
Among the biggest risers on the S&P 500 on Wednesday January 13 was Eli Lilly and Company ($LLY), popping some 3.75% to a price of $185.50 a share with some 7.27 million shares trading hands.
Starting the day trading at $179.83, Eli Lilly and Company reached an intraday high of $187.62 and hit intraday lows of $179.34. Shares gained $6.7 apiece by day’s end. Over the last 90 days, the stock’s average daily volume has been n/a of its 956.58 million share total float. Today’s action puts the stock’s 50-day SMA at $n/a and 200-day SMA at $n/a with a 52-week range of $117.06 to $189.31.
Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly’s key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Eli Lilly and Company has its corporate headquarters located in Indianapolis, IN and employs 33,625 people. Its market cap has now risen to $177.45 billion after today’s trading, its P/E ratio is now n/a, its P/S n/a, P/B 36.73, and P/FCF n/a.